← IQVIA overview

IQVIA vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

IQVIA Holdings Inc (IQV)

Q3 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

August 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

Latest
▲3▼1

IQVIA's record bookings, AI launches, and cheap valuation drive the stock

  • Record bookings and raised guidance IQVIA's second-quarter results beat expectations, with adjusted earnings up 12.1% and revenue up 8.7%. Crucially, new clinical bookings jumped 19% to $3.2 billion, a record, and the company raised its full-year revenue outlook. Strong bookings signal future growth, which supports a higher stock price.

    This is the core fundamental driver: accelerating demand and raised guidance directly boost investor confidence and the stock's value.

  • AI products speed up clinical trials IQVIA launched two AI-powered platforms: Predictive Clinical Development and Life Science Models. These tools aim to cut trial delays by up to two years and improve prediction accuracy. If adopted, they could win more business and make IQVIA's services more valuable, pushing the stock up over time.

    New AI products are a key growth catalyst, showing innovation that can expand IQVIA's market and margins.

  • Cheap valuation and buybacks IQVIA trades at a forward P/E of 16.2, much lower than peers like Penumbra, and has a Value grade of B. The company also bought back $398 million of shares in Q2, reducing the share count. A low valuation plus buybacks can attract investors and lift the stock.

    Valuation and capital returns are direct price drivers, making IQVIA look attractive relative to peers.

  • Higher interest costs from new debt IQVIA priced $2 billion in senior notes at 6.375% to refinance older 5% debt. This raises annual interest expense by about $27.5 million, slightly reducing future profits. While manageable, it's a headwind that could weigh on the stock.

    This is the main counterweight: increased debt costs pressure earnings, balancing the positive drivers.

▲4

IQVIA beats Q2, raises 2026 outlook on record bookings

  • Q2 beat and raised 2026 guidance IQVIA reported Q2 revenue of $4.37 billion (up 8.7%) and earnings of $3.15 per share, beating estimates. Management raised full-year 2026 revenue and profit guidance, pushing shares up 5% after hours and nearly 14% the next day. This directly lifts the stock because future profits are now expected to be higher.

    The earnings beat and guidance raise are the core new event that moved the stock this period.

  • Record $3.15B bookings and $34.2B backlog IQVIA's R&D Solutions unit signed a record $3.15 billion in new contracts in Q2, up 19% from a year ago. Its total contracted backlog hit a record $34.2 billion, with $9.2 billion expected to convert to revenue within 12 months. This signals strong future demand and supports the stock.

    Record bookings and backlog are new, concrete evidence of future revenue growth that investors care about.

  • Medera collaboration expands gene therapy reach IQVIA announced a partnership with Medera to combine its clinical trial and commercialization network with Medera's cardiac gene therapy and human-based drug discovery platforms. This expands IQVIA's presence in cell and gene therapy, a high-growth area, and supports its long-term R&D pipeline.

    This is a new strategic partnership that broadens IQVIA's technology and service offerings.

  • Stock up 42% in three months on strong results IQVIA shares have rallied 41.5% over the past three months, far outpacing the industry and the S&P 500. The run reflects the strong bookings, raised guidance, and $950 million of share buybacks in the first half of 2026. Momentum can attract more buyers, but also means the stock is no longer cheap.

    This summarizes the market's reaction to the new fundamentals and highlights the strong momentum, while noting valuation risk.

Agilent Technologies Inc (A)

Q3 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

August 2026
▲3

Agilent Q3 Beat, China Rebound, Reshoring Orders Drive August Gains

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with 18% EPS growth and raised full-year guidance, sending shares up 9.6%. This shows the company is growing faster than expected and gives investors confidence in its momentum.

    This is the main new financial event that directly boosted the stock in August.

  • China rebound and reshoring orders China rebounded with double-digit pharma growth, and Agilent booked its first reshoring orders from five top-10 pharma companies. This reduces reliance on any single market and taps new demand as drug production moves closer to home.

    These are new geographic and customer wins that expand Agilent's revenue base.

  • Diagnostics expansion via FDA/EU approvals Agilent won FDA and EU approvals for PD-L1 cancer tests, expanding its diagnostics business. This opens new revenue streams in cancer care and strengthens its position in the fast-growing pathology market.

    New product approvals are concrete growth catalysts for the diagnostics segment.

  • AI and automation tailwinds vs. competition and sector sensitivity AI product launches, lab automation, and multi-year instrument replacement cycles add steady tailwinds. But Danaher's Leica is expanding in pathology, and the life sciences tools sector remains sensitive to growth-outlook cuts, which could cap gains if investors worry about market share or a broader slowdown.

    This captures both the positive long-term drivers and the real risks that could limit upside.

Latest
▲4

Agilent's Q3 beat and China/reshoring momentum drive shares higher

  • Q3 earnings beat and raised guidance Agilent beat Q3 estimates with non-GAAP EPS up 18% and raised full-year guidance, sending shares up 9.6% since the report. Broad demand across pharma and China, plus Advanced Therapeutics up nearly 30%, shows the core business is accelerating and supports a higher stock price.

    This is the biggest new positive catalyst this period, directly driving the stock higher.

  • China strength and reshoring orders Management said China delivered double-digit growth in pharma and food and high-teens in advanced materials, and Agilent booked its first reshoring orders from five top-10 pharma companies. This opens a new demand source and supports long-term growth, pushing the stock up.

    New geographic and reshoring demand drivers that were not previously reported and directly boost growth outlook.

  • Instrument replacement cycle and lab automation Agilent is less than halfway through its liquid chromatography replacement cycle, worth 200-300 basis points of growth, and about a quarter through gas chromatography, worth 100 basis points. These multi-year upgrades plus lab automation provide a steady tailwind for revenue and the stock.

    New details on replacement cycles and automation that underpin future growth, not previously reported.

  • New AI product launches and investment Agilent launched a Gen5 AI cell identification module for BioTek imagers and led a multimillion-dollar investment in HALO X-ray Technologies. These moves expand its AI and security screening offerings, signaling innovation that can drive future sales and support the stock.

    New product and investment news that shows Agilent is advancing technology, a positive for future growth.

▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.